The Hello Bar is a simple web toolbar that engages users and communicates a call to action.

February 4, 2012

Eli Lilly and Company Named a Top Global Company for Leaders

Eli Lilly and Company (NYSE: LLY) has been named one of the top 25 global companies for leaders by Aon Hewitt in partnership with FORTUNE and the RBL Group. Lilly ranked 16th on the Global 25 list and 12th on the North American list. The survey is one of the most comprehensive studies of talent [...]

Lilly Announces First and Only International, Prospective Observational Study Designed to Understand Barriers to Progression of Insulin Treatment

Eli Lilly and Company (NYSE: LLY) today announced it is conducting the first major international, prospective observational study designed to understand the real-world obstacles that people with type 2 diabetes face that prevent them from reaching their ultimate treatment goals. Many people with diabetes who take daily insulin resist a progression of insulin therapy that [...]

F.A.C.E. Diabetes and Anthony Anderson Ask Americans to Rethink Generation D

For the second year in a row, award-winning actor and comedian Anthony Anderson is teaming up with Eli Lilly and Company’s Fearless African-Americans Connected and Empowered (F.A.C.E.) Diabetes initiative to remove the stereotype of Generation D—the belief that type 2 diabetes is an older person’s disease. Formerly known as “adult-onset” diabetes, type 2 diabetes is [...]

Lilly to Recognize Employees Who Have Served Our Country Through the Military

U.S. military veterans employed by Eli Lilly and Company (NYSE: LLY) will be recognized for their service to the country during a special Veterans Recognition Event at the Lilly Corporate Center 4 p.m. Monday, Nov. 14. The event is sponsored by the Veterans Leadership Network (VLN), an employee resource group at Lilly, and by Employer [...]

Lilly CEO Says Appropriate Assessment of Both Benefits and Risks Critical in Regulatory Process

To sustain medical innovation, the FDA must accelerate the adoption of a Benefit-Risk framework to inform decision-making in the regulatory process, said John Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company (NYSE: LLY). In an address at the FDA News Fourth Annual Risk Management and Drug Safety Summit, Lechleiter called for a [...]

ALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer

Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has granted approval for the use of ALIMTA® (pemetrexed for injection) as a single agent for continuation maintenance therapy in patients with a particular type of lung cancer, called advanced nonsquamous non-small cell lung cancer (NSCLC). The approval is based on clinical trial [...]

New Study Shows Cialis(R) Significantly Improved Study Endpoints in Men with Both Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia

INDIANAPOLIS – Eli Lilly and Company (NYSE: LLY) announced today that a pivotal Phase III study of Cialis® (tadalafil) tablets 5 mg for once daily use met its co-primary endpoints, significantly improving measures of both erectile dysfunction (ED) and signs and symptoms of benign prostatic hyperplasia (BPH) in men with both conditions. The study is [...]

Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference

INDIANAPOLIS – Eli Lilly and Company (NYSE: LLY) will bring one of its patient education programs to Washington, D.C., September 21-24 during the 2011 Annual Legislative Conference presented by the Congressional Black Caucus Foundation at the Walter E. Washington Convention Center. In attendance will be Eli Lilly and Company’s Fearless African-Americans Connected and Empowered (F.A.C.E.) [...]

Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes

RIDGEFIELD, Conn., and INDIANAPOLIS, – Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets (to be marketed under the trade name Trajenta® in Europe) for the treatment of adults with type 2 diabetes. The European Commission has approved linagliptin in combination [...]

Eli Lilly India and Lupin Announce Strategic Collaboration to Help Fight the Battle Against Diabetes

NEW DELHI and MUMBAI, India, – Eli Lilly India (Lilly) and Lupin Limited (Lupin)today announced they have entered into a strategic collaboration to promote and distribute Lilly’s Huminsulin range of products, including Huminsulin R(TM), Huminsulin NPH(TM), Huminsulin 50/50(TM), Huminsulin 30/70(TM) and Humapen Ergo II. Lupin’s India formulations business will promote and distribute the range of [...]

© Rx Times, LLC 2011. All rights reserved. All products denoted with ™ and ® are trademarks or registered trademarks of Rx Times, LLC and/or its affiliates.